ReviewFrontiers in oncology2026
Clinical stratification utility of HER2, PD-L1, MSI/MMR, and CLDN18.2 in conversion therapy for gastric cancer: narrative review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with gastric cancer considered for conversion therapy present with locally advanced or metastatic disease, where surgery alone or conventional chemotherapy often provides limited benefit. Conversion therapy aims to reduce tumor burden through systemic treatment, reassess treatment response over time, and create an opportunity for radical surgery with complete tumor removal. This approach is mainly considered for patients with initially unresectable, borderline resectable, or limited metastatic disease. However, because not all patients benefit from this strategy, careful selection of those most likely to respond to systemic therapy and proceed to surgery is essential. With the development of immunotherapy and targeted therapy, conversion therapy for gastric cancer has shifted from empiric chemotherapy toward biomarker-guided individualized treatment. HER2 status may guide anti-HER2 therapy, PD-L1 may help identify patients who benefit from immunotherapy combined with chemotherapy, MSI-H/dMMR suggests greater sensitivity to immunotherapy, and CLDN18.2 provides a new targeted option, particularly for HER2-negative disease. This review examines the clinical value of HER2, PD-L1, MSI/MMR, and CLDN18.2 in treatment selection, response prediction, repeated reassessment, and surgical timing. These biomarkers may help identify patients with treatment-sensitive disease who warrant surgical reassessment. However, because most supporting evidence is extrapolated from palliative/metastatic or perioperative trials, such evidence should not be interpreted as demonstrating improved conversion-surgery or R0-resection rates, pathological response, or postoperative disease-free survival in conversion-therapy populations; surgical eligibility remains dependent on comprehensive clinical and multidisciplinary assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.